Johnson & Johnson (JNJ) – Q1 reflected continued operational sales and earnings growth

in , on June 11, 2019

JNJ’s sales grew by 0.1% to $20bn in Q1FY19 with 3.9% operational growth and 5.5% adjusted operational sales growth. Adjusted EPS increased by 1.9% to $2.1 and GAAP EPS decreased by 13.1% to $1.39

Number of Pages – 54

Contents:

Executive Summary

Financial Statements

–  Income Statement and Forecast

–  Balance Sheet

–  Cash Flow

–  Q1FY19  Results – Overview

–  Q1FY19 – Segment Performance

–  Q1FY19 – Developments

–  FY19 Guidance

–  Conclusion

–  GAAP to Non-GAAP Reconciliation

Historical Performance

–  Key Ratios

–  Profitability Ratios, Asset Turnover Ratio, Growth Ratio

–  Per Share Items and Key Ratios

–  Key Balance Sheet Items and Cash Flow Items

–  P/E Band

Product Performance and Key Developments

–  Ownership

–  Competitors

–  Key Developments

Valuation and Consensus Performance

–  Relative Valuation

–  Analyst Recommendations

Market Price Performance

CrispIdea Coverage Chart 

Release Information

  • Released
    :

    June 11, 2019

  • Last Updated
    :

    June 11, 2019